Lataa...
Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review
BACKGROUND: Tafenoquine is an 8-aminoquinoline anti-malarial drug recently approved as a single-dose (300 mg) therapy for Plasmodium vivax relapse prevention, when co-administered with 3-days of chloroquine or other blood schizonticide. Tafenoquine 200 mg weekly after a loading dose is also approved...
Tallennettuna:
| Julkaisussa: | Malar J |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7071640/ https://ncbi.nlm.nih.gov/pubmed/32169086 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12936-020-03184-x |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|